Research progress on the application and safety of CD20 monoclonal antibody in children with refractory nephrotic syndrome
10.3760/cma.j.cn114015-20241108-00138
- VernacularTitle:CD20单克隆抗体在难治性肾病综合征患儿的应用与安全性研究进展
- Author:
Jing WEN
1
;
Jianwei QIN
;
Weihao JIANG
;
Shitian XU
Author Information
1. 重庆市合川区人民医院药剂科，重庆 401500
- Publication Type:Journal Article
- Keywords:
Nephrotic syndrome;
Antibody, monoclonal;
Cluster of differentiation 20 monoclonal antibody;
Drug safety;
Pediatric medications;
Refractory nephrotic syndr
- From:
Adverse Drug Reactions Journal
2025;27(6):356-361
- CountryChina
- Language:Chinese
-
Abstract:
The use of CD20 monoclonal antibody in the treatment of children with refractory nephrotic syndrome (RNS) is a novel drug therapy in recent years. Some CD20 monoclonal antibodies have positive efficacy and few adverse reactions, which can reduce the use of hormone drugs and immunosuppressants to a certain extent. However, the treatment of nephrotic syndrome is off-label, and the application time in clinic is not long, especially for children′s RNS, and more high-quality clinical studies are still needed for long-term efficacy and safety. The application and safety research progress of CD20 monoclonal antibody (including rituximab, ofatumumab, obinutuzumab, etc.) in the treatment of children with RNS from the aspects of mechanism of action, clinical application, pharmacokinetic characteristics, adverse reactions monitoring, and prevention are reviewed in this article, so as to provide reference for rational and safe clinical use.
